Etavopivat Demonstrates Success in Achieving Co-Primary Endpoint

Novo Nordisk (NVO)'s etavopivat, an investigational treatment for Sickle Cell Disease (SCD), has demonstrated significant efficacy in the Phase 3 HIBISCUS trial. Etavopivat works through an innovative mechanism by activating pyruvate kinase R (PKR) in red blood cells, increasing intracellular energy, and preventing red blood cell deformation. In this trial, 385 SCD patients aged 12 and older were administered the drug for 52 weeks, resulting in a remarkable 27% reduction in the annualized rate of vaso-occlusive crises (VOCs) compared to the placebo group. The time to first VOC also significantly increased in the etavopivat group, with a median of 38.4 weeks compared to 20.9 weeks in the placebo group, demonstrating the potential to dramatically improve patients' quality of life.

Reduction in Red Blood Cell Destruction and Significant Improvement in Anemia

Furthermore, etavopivat showed excellent results in alleviating chronic anemia symptoms in patients. At week 24, the proportion of patients with a hemoglobin increase of 1 g/dL or more was 48.7% in the etavopivat group, compared to 7.2% in the placebo group, representing a substantial adjusted response rate difference of approximately 41.2%. This suggests that etavopivat can inhibit hemolysis, the premature destruction of red blood cells, and restore oxygen-carrying capacity, potentially preventing systemic organ damage in patients. In terms of safety, it showed a favorable tolerability profile consistent with previous clinical trials, paving the way for the submission of a New Drug Application (NDA) to the FDA in the second half of 2026.

Securing Pipeline Through Acquisition of Forma Therapeutics

The success of this clinical trial is underpinned by Novo Nordisk's strategic mergers and acquisitions (M&A). In 2022, Novo Nordisk acquired Forma Therapeutics for a total of USD 1.1 billion, securing etavopivat as a key asset. The deal structure involved a full upfront cash payment without separate milestone payments or royalties, making it a highly efficient portfolio with no additional costs upon commercialization. This investment by Novo Nordisk, aimed at establishing a leading position in the SCD treatment field, has now yielded positive results.

Opportunity for a Dominant Oral Therapy Following Withdrawal of Competing Drug

The SCD market is currently undergoing significant changes, further highlighting the commercial value of etavopivat. Oxbryta, a leading oral competitor from Pfizer (PFE), was withdrawn from the global market in September 2024 due to serious safety concerns, including an increased risk of death. This has created a significant gap in the oral therapy market, and if etavopivat is approved, it will be well-positioned to quickly gain market share. Although gene therapies such as Casgevy from Vertex (VRTX) and CRISPR Therapeutics (CRSP) have emerged, their high cost and complex administration procedures make etavopivat, a convenient once-daily oral medication, a highly competitive option.

Poised for Growth in the Expanding Global SCD Treatment Market

The global SCD treatment market is expected to grow rapidly from approximately USD 4.73 billion in 2026 to approximately USD 20.47 billion in 2034, with an annual growth rate of 15-20%. Building on the success of the Phase 3 trial, Novo Nordisk plans to submit a new drug application to the FDA in the second half of 2026 and begin the commercialization process. By expanding beyond obesity and diabetes into the new high-value area of rare blood diseases, the company is expected to enhance its corporate value and achieve balanced pipeline growth.